Paper
0
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Authors
Alanna Morrison,Viktoria Gusarova
Colm O’Dushlaine,Omri Gottesman,Jesus Trejos,Charleen Hunt,Cristopher Hout,Lukas Habegger,David Buckler,Ka-Man Lai,Joseph Leader,Michael Murray,Marylyn Ritchie,H. Kirchner,David Ledbetter,John Penn,Alexander Lopez,Ingrid Borecki,John Overton,Jeffrey Reid,David Carey,Andrew Murphy,George Yancopoulos,Aris Baras,Jesper Gromada,Alan Shuldiner,Frederick Dewey
+25 authors
,Colm Ó'DúshláinePublished
Mar 2, 2016
Show more
Save
Tip0
TipSave
Abstract
Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.